Escherichia coli Infections - Pipeline Review, H2 2020

November 2020 | 200 pages | ID: EB1061EB5D6EN
Global Markets Direct

Abstracts

Escherichia coli Infections - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H2 2020, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.

Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 1, 27 and 19 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 8 and 13 molecules, respectively.

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Escherichia coli Infections- Overview
Escherichia coli Infections- Therapeutics Development
Escherichia coli Infections- Therapeutics Assessment
Escherichia coli Infections- Companies Involved in Therapeutics Development
Escherichia coli Infections- Drug Profiles
Escherichia coli Infections- Dormant Projects
Escherichia coli Infections- Discontinued Products
Escherichia coli Infections- Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Escherichia coli Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Escherichia coli Infections - Pipeline by ABAC Therapeutics SA, H2 2020
Escherichia coli Infections - Pipeline by Affilogic SAS, H2 2020
Escherichia coli Infections - Pipeline by AstraZeneca Plc, H2 2020
Escherichia coli Infections - Pipeline by Atterx Biotherapeutics Inc, H2 2020
Escherichia coli Infections - Pipeline by BB100 LLC, H2 2020
Escherichia coli Infections - Pipeline by Biomendics LLC, H2 2020
Escherichia coli Infections - Pipeline by Bugworks Research India Pvt Ltd, H2 2020
Escherichia coli Infections - Pipeline by ContraFect Corp, H2 2020
Escherichia coli Infections - Pipeline by Debiopharm International SA, H2 2020
Escherichia coli Infections - Pipeline by Eligo Bioscience SA, H2 2020
Escherichia coli Infections - Pipeline by EnBiotix Inc, H2 2020
Escherichia coli Infections - Pipeline by EveliQure Biotechnologies GmbH, H2 2020
Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Escherichia coli Infections - Pipeline by Forge Therapeutics Inc, H2 2020
Escherichia coli Infections - Pipeline by GlyProVac ApS, H2 2020
Escherichia coli Infections - Pipeline by Hsiri Therapeutics LLC, H2 2020
Escherichia coli Infections - Pipeline by Johnson & Johnson, H2 2020
Escherichia coli Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2020
Escherichia coli Infections - Pipeline by Linnaeus Bioscience Inc, H2 2020
Escherichia coli Infections - Pipeline by Meiji Seika Pharma Co Ltd, H2 2020
Escherichia coli Infections - Pipeline by Melinta Therapeutics Inc, H2 2020
Escherichia coli Infections - Pipeline by Merck & Co Inc, H2 2020
Escherichia coli Infections - Pipeline by Microbiotix Inc, H2 2020
Escherichia coli Infections - Pipeline by Navigen Inc, H2 2020
Escherichia coli Infections - Pipeline by Neoculi Pty Ltd, H2 2020
Escherichia coli Infections - Pipeline by Northern Antibiotics Oy, H2 2020
Escherichia coli Infections - Pipeline by Nosopharm SAS, H2 2020
Escherichia coli Infections - Pipeline by Novabiotics Ltd, H2 2020
Escherichia coli Infections - Pipeline by Ostrich Pharma USA Inc, H2 2020
Escherichia coli Infections - Dormant Projects, H2 2020
Escherichia coli Infections - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Escherichia coli Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020